P
Pramod K. Srivastava
Researcher at University of Connecticut
Publications - 405
Citations - 29058
Pramod K. Srivastava is an academic researcher from University of Connecticut. The author has contributed to research in topics: Heat shock protein & Antigen. The author has an hindex of 79, co-authored 390 publications receiving 27330 citations. Previous affiliations of Pramod K. Srivastava include Gujarat University & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
CD11c+ MHCIIlo GM-CSF-bone marrow-derived dendritic cells act as antigen donor cells and as antigen presenting cells in neoepitope-elicited tumor immunity against a mouse fibrosarcoma.
Hakimeh Ebrahimi-Nik,William L. Corwin,Tatiana Shcheglova,Alok Das Mohapatra,Ion I. Mandoiu,Pramod K. Srivastava +5 more
TL;DR: It is shown that dendritic cells but not macrophages possess superior adjuvanticity, and that the CD11c+ MHCIIlo sub-set, distinguishable by a distinct transcriptional profile including a higher expression of heat shock protein receptors CD91 and LOX1, mannose receptors and TLRs, is significantly superior to the CD 11c+MHCIIhi sub- set.
Journal Article
A Multicentre, Open label, Randomized, Comparative, Parallel Group, Active-controlled, Phase III Clinical Trial to Evaluate Safety and Efficacy of Arbekacin Sulphate Injection versus Vancomycin Injection in Patients Diagnosed with MRSA Infection.
Dube A,Deb Ak,Das C,Padhye D,Bhalla H,Basu I,Bs M,Pramod K. Srivastava,Agarwal R,R.P. Agrawal,Singh Rm,Kurlekar U,Pawar R,Shahavi,Ambrish Srivastava +14 more
TL;DR: Overall cure rate of MRSA infection (clinical as well as microbiological cure) was comparable in both the treatment groups i.e. 97.5% in Arbekacin group and 100% in Vancomycin group, suggesting that ArbekACin can be considered as safe and effective alternative to vancomYcin in the management of MR SA infections.
Journal Article
Prognostic factors in Guillain-Barre' syndrome.
TL;DR: Prospective prognostic evaluation of various clinical and investigative parameters in 24 patients of Guillain-Barre' syndrome revealed poor prognosis in patients having rapid onset of illness, severe degree of paralysis and muscle wasting, prolonged period of peak paralysis lasting for more than 2 weeks and delayed onset of recovery not commencing within 3 weeks from the onset of weakness.
Journal ArticleDOI
Immune response to mutant neo-antigens: Cancer's lessons for aging
TL;DR: It is hypothesized that, at least under inflammatory conditions, immune responses against such neo-antigens may lead to the elimination or functional impairment of normal cells, thus contributing to aging.
Patent
Identification of tumor-protective epitopes for the treatment of cancers
TL;DR: In this article, a novel index called the Differential Agretopic Index (DAI) for the epitope which allows prediction of whether immunization with a particular epitope will be protective against the tumor was proposed.